Clinical trials: HPV-associated Cancer
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Human Papilloma Virus, Cervical Cancer
M7824 in Subjects With HPV Associated Malignancies
Background: In the United States, each year there are more than 30,000 cases of human papillomavirus (HPV) associated cancers. Some of these cancers are often incurable and are not improved by standard therapies.
- Conditions
- Human Papilloma Virus, Cervical Cancer, Oropharyngeal Cancer, Anal Cancer
- Trial name
- NCT03427411
- Testing
- M7824
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Squamous Cell Carcinoma (SCC)
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Background: Cancers in and around the mouth associated with human papilloma virus (HPV) are common. Two treatments (the drug pembrolizumab and the HPV vaccine PRGN-2009) have been shown to work well when used individually against…
- Trial name
- NCT05996523
- Testing
- PRGN-2009, Pembrolizumab, EKG
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Precancerous Condition
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01084083
- Testing
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel
- Where
- 121 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eastern Cooperative Oncology Group
Cervical Cancer, HPV Cancers
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
Background: More than 30,000 cases of human papillomavirus (HPV) associated cancers occur annually in the United States. When these cancers spread, they do not respond well to standard treatments and are often incurable.
- Conditions
- Cervical Cancer, HPV Cancers, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04287868
- Testing
- PDS0101, M7824, NHS-IL12
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Papillomavirus Infections, Oropharyngeal Neoplasms
E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer
Background: The therapy used in this study is called E7 T-cell receptor (TCR) T cell therapy. This therapy is a type of treatment in which a participant's T cells (a type of immune system cell) are changed in the laboratory to…
- Trial name
- NCT04015336
- Testing
- E7 T-Cell Receptor (TCR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Vaginal Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT02280811
- Testing
- Fludarabine, Cyclophosphamide, E6 TCR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Cancer
Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma
This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccine delivered by electroporation (EP) to participants with human papilloma virus (HPV) associated head and neck…
- Trial name
- NCT02163057
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Inovio Pharmaceuticals
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
This phase II/III trial studies how well a reduced dose of radiation therapy works with nivolumab compared to cisplatin in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer that is early in its…
- Conditions
- Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT03952585
- Testing
- Biopsy Procedure, Biospecimen Collection, Cisplatin
- Where
- 494 sites in United States, Canada
- Volunteers
- 384 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Human Papilloma Virus
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination…
- Trial name
- NCT03162224
- Testing
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Where
- 14 sites in United States
- Volunteers
- 35 people
- Sponsor
- MedImmune LLC
Carcinoma, Squamous Cell, Head and Neck Neoplasms
P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
The primary objective of this study is to evaluate whether genomic based risk-stratification can be used in deciding whether to de-intensify in patients with Human Papillomavirus (HPV)-associated Oropharyngeal Squamous Cell…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT03077243
- Testing
- Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer, Oropharyngeal Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Background: The human papillomavirus (HPV) can cause a number of cancers, including cervical and throat cancers. The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white…
- Conditions
- Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer
- Trial name
- NCT01585428
- Testing
- Fludarabine, Cyclophosphamide, Young TIL
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
This clinical trial will evaluate a new combination of pembrolizumab, HPV-16 E6/E7 specific therapeutic vaccination (ISA101b) and cisplatin-based chemoradiotherapy for patients with newly diagnosed, local-regionally advanced…
- Trial name
- NCT04369937
- Testing
- IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dan Zandberg
Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer.
- Trial name
- NCT04580446
- Testing
- Hypofractionated intensity modulated radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Cancer, Head and Neck Neoplasms
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
Background: Some people who get head and neck cancer will need surgery to treat their cancer. Research suggests that immunotherapy drugs may help fight head and neck cancer if given before surgery.
- Trial name
- NCT04247282
- Testing
- M7824, N803, TriAd vaccine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Infections, Papillomavirus
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
This extension study is conducted to assess the efficacy of the GSK 580299 vaccine against cervical intraepithelial neoplasia (CIN) lesions, cervical cancer and cytological abnormalities associated with human papillomavirus…
- Trial name
- NCT00929526
- Testing
- Liquid-based cytology (LBC) sampling, Blood sampling
- Where
- 13 sites in Japan
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-Associated Malignant Neoplasm, HIV Infections
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
This study is being done to understand how many people with HIV (PWH) present for cancer care across the AIDS Malignancy Consortium in the United States and if there are reasons that some PWH choose to participate, or not in…
- Conditions
- HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma
- Trial name
- NCT05510908
- Testing
- Non-Interventional, Non-Interventional Follow-up
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 460 people
- Sponsor
- AIDS Malignancy Consortium
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
OPSCC N0 Nodal Control With Reduced IMRT
The dose of radiation most commonly used to treat oropharyngeal cancer results in side effects including sores in the mouth and throat, dry mouth and thick saliva, loss or altered taste, swallowing problems including pain or…
- Trial name
- NCT01891695
- Testing
- 39.6 Gy radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Paul W. Read, MD
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
This phase II trial studies how well alpelisib works in treating participants with human papillomavirus(HPV)-associated stage I-IVA head and neck cancer that can be removed by surgery.
- Conditions
- CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7
- Trial name
- NCT03601507
- Testing
- Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona